Sylvie Pichon

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

Paul Griffiths, Anna Stanton, Erin McCarrell et al. · The Lancet · 2011 · 390 citations · Full text

Vaccination, Mf59 Adjuvant, Transplantation +10

Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial

David I. Bernstein, Flor M. Muñoz, S. Todd Callahan et al. · Vaccine · 2015 · 231 citations · Full text

Vaccination, Vaccine Safety, Randomized Clinical Trial +8

An Adjuvanted, Low‐Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross‐Reactive Immune Responses in Healthy Adults

Karin Levie, Isabel Leroux‐Roels, Karel Hoppenbrouwers et al. · The Journal of Infectious Diseases · 2008 · 117 citations · Full text

Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies

Ilona Baraniak, Barbara Kropff, Lyn Ambrose et al. · Proceedings of the National Academy of Sciences · 2018 · 115 citations · Full text

Glycoprotein B Vaccine Is Capable of Boosting Both Antibody and CD4 T-Cell Responses to Cytomegalovirus in Chronically Infected Women

Steffanie Sabbaj, Robert F. Pass, Sylvie Pichon et al. · The Journal of Infectious Diseases · 2011 · 112 citations · Full text